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It is my pleasure to welcome you to the latest issue of the JHN Journal.
Spine surgery is continuously evolving with improvements in techniques, 
and advancements in technology. As always, the Spine Surgeons at 
Jefferson Health are at the forefront of this change.
Whether it’s the adoption of image guidance and robotics, implementation 
of new minimally invasive techniques, advancements in neuromodulation, 
or collaboration in novel therapies for spinal cord injury, Jefferson 
continues to lead the way.    
This very special issue of the JHN journal will highlight some of the 
important work that the Neurological Spine Surgeons at Thomas Jefferson 
University Hospital, and Jefferson Abington Hospital are doing to improve 
patient outcomes through advancements in technology.
I am very proud of the work that we do, and I am certain that the articles 
contained within this issue will prove to be enlightening. 
Sincerely,
 
Joshua E. Heller, MD, MBA 
Associate Professor of Neurological 
and Orthopaedic Surgery 
 
Dear Colleague, 
Joshua E. Heller, MD, MBA
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Technique – Fluoroscopy
After administration of general endo-
tracheal anesthesia and placement of 
neuromonitoring leads, the patient is 
positioned prone on a Jackson table 
with careful attention to adequately 
padding pressure points and ensuring 
the abdomen hangs free. Fluoroscopy is 
used to mark the skin on the ipsilateral 
side the location of the sacral ala as well 
as the posterior aspect of the sacral 
canal. This serves as a marking point for 
the incision and helps with orientation 
of the implants (Figures 1-2). The skin is 
then prepped and draped in standard 
fashion. The incision is created with a 
#10 blade and the subcutaneous tissue is 
dissected with monopolar electrocautery. 
A hemostat is used to open the fascia. A 
Steinmann pin is placed at the level of the 
ilium with lateral fluoroscopic guidance 
at a location below the sacral ala. Pelvic 
inlet and outlet views are obtained to 
demonstrate adequate positioning of 
the pin relative to the ilium, SI joint, and 
neural foramina (Figure 3). The first pin 
is then tamped through the ilium, across 
the SI joint, and into the sacrum. The soft 
tissue dilator is then placed over the pin, 
followed by a soft tissue protector. A 
drill is then advanced over the pin and 
advanced across the SI joint. The broach 
is then advanced across the SI joint 
with fluoroscopic guidance on lateral, 
pelvic inlet, and pelvic outlet views. 
The broach is then removed. The first 
implant is then advanced over the pin 
and tamped into position using fluoro-
scopic guidance (Figure 4). A parallel pin 
guide is then used to assist with place-
ment of the next Steinmann pin inferior 
to the first implant, and the procedure 
is repeated for a second implant. The 
parallel pin guide is then used to place 
a Steinmann pin in the ideal location of 
the third implant relative to the first two. 
The authors preference is to place the 
third implant it in a position anterior and 
inferior to the first. The same procedure 
is repeated for placement of the final 
INTRODUCTION
Low back pain is a common affliction impacting patients worldwide. The burden of 
low back pain on modern society in terms of direct costs associated with diagnosis and 
treatment, as well as indirect costs such as time missed from work for both patients 
and caregivers, is estimated to be as high as $100 billion annually in the United States 
alone.1,2 Up to 2-3% of physician visits are thought to be related to chronic low back 
pain.1,3 While the traditional focus of healthcare providers has been on lumbosacral 
pathology, sacroiliac joint dysfunction is an underappreciated and underdiagnosed 
cause of low back pain. Previous studies3-8 have suggested that 15-30% of chronic low 
back pain is due to pathology located in the sacroiliac joint. Historically, recognition 
of this pathology was difficult, limited by lack of standardized diagnostic criteria and 
disease-specific outcome measures. Traditional treatment focused on conservative 
therapy, such as physical therapy with focus on core and pelvic stability, orthoses, 
pain and anti-inflammatory medication, weight loss, intra- or peri-articular injec-
tions, and radiofrequency ablation.4,5,9-12 Early surgical intervention came in the form 
of morbid open approaches often utilizing iliac crest autografting. More recently, 
minimally invasive techniques for sacroiliac fusion have been developed that allow 
for significant sparing of muscle dissection, shorter operating room times and blood 
loss, reduced length of stay, and fewer complications.13-17 Such techniques are often 
performed with fluoroscopic guidance. However, three-dimensional sacral anatomy 
can be challenging to conceptualize on fluoroscopic imaging and several centers are 
now beginning to perform the procedure utilizing image-guidance with intraoperative 
CT data. This is particularly helpful in patients with transitional lumbosacral anatomy 
or those undergoing revision procedures. Complications such as pseudarthrosis and 
neural injuries, while rare, are often associated with need for revision surgery and 
poorer outcome.18,19 The transition to CT-based image-guidance aims to reduce such 
complications. The purpose of this study is to review our series of minimally invasive 
sacroiliac fusion with a focus on safety and complications, and to review differences 
in these parameters between patients undergoing fluoroscopic technique versus 
CT-based image-guidance. 
METHODS
We performed a PubMed literature search utilizing the following terms: sacroiliac 
joint fusion, SI joint fusion, minimally invasive, complications, image guidance. Only 
English language articles were reviewed. All studies documenting large case series and 
prospective trials regarding minimally invasive sacroiliac joint fusion were included. 
The data extraction was performed by two reviewers (CH, DF), and reviewed by the 
senior author (JH). The selected studies were analyzed, and relevant results were 
reviewed. In addition, a retrospective review of minimally invasive sacroiliac joint 
fusion procedures performed at our institution was performed spanning 2013-present. 
Patient demographics, type of imaging used (traditional fluoroscopy versus CT and 
Stealth image guidance) follow-up, and complications were recorded. Complications 
of particular interest were neurologic complications, pseudarthrosis, and need for revi-
sion surgery, among others. Comparisons were made between patients undergoing 
fluoroscopy and CT/Stealth guidance.
Christian Hoelscher, MD; Daniel Franco, MD; Joshua Heller, MD, MBA 
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, 
Pennsylvania, 19107 
Sacroiliac Joint Fusion – Impact of a New Image-
Guidance Protocol on Safety and Complications
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the location of the posterior aspect of 
the sacral canal on the ipsilateral side. 
This serves as the incision and reference 
for graft placement. The skin is then 
incised with a #10 blade, with dissection 
carried down through the subcutaneous 
tissue with monopolar electrocautery. 
The fascia is opened with a hemostat. 
The navigated universal drill guide is then 
placed to the level of the ilium (Figure 5). 
The first implant is planned and transferred 
to the work station (Figure 6). The drill 
guide is then used to place a guidewire 
through the ilium to the planned depth. A 
soft tissue dilator is then placed over the 
wire, followed by a soft tissue protector. 
The navigated drill is then used to drill 
over the guidewire across the ilium, the 
SI joint, and into the sacrum. The drill is 
removed, and a navigated broach is then 
advanced and tamped down the same 
trajectory. Neuromonitoring is then 
checked and confirmed to be unchanged 
from baseline. The soft tissue protector 
is then removed. A parallel pin guide 
with a navigated universal drill guide is 
then used to mark the location for the 
starting point of the second implant, 
inferior to the first graft. The process is 
repeated for the second and third grafts. 
Neuromonitoring is checked after place-
ment of each graft. Once all grafts have 
been placed, a second intra-operative 
CT is obtained to confirm appropriate 
positioning. The wound is then copiously 
irrigated with antibiotic solution. The 
soft tissue is anesthetized with Marcaine 
solution. The deep dermal layer is closed 
with 2-0 vicryl suture in an inverted 
fashion and the skin is closed with a 4-0 
monocryl subcuticular suture, followed 
by skin glue and a sterile dressing. A 
single monocryl suture is placed in the 
contralateral PSIS pin site. Figure 7 shows 
an example of post-operative imaging 
demonstrating hardware position.
Sacroiliac Joint Fusion
implant. Neuromonitoring signals are 
checked after placement of each implant. 
Final fluoroscopic images are obtained 
confirming trajectory and final posi-
tion across the SI joint into the sacrum 
without breach of the neuroforamina. 
The wound is then copiously irrigated 
with antibiotic solution. The soft tissue 
is anesthetized with Marcaine solution. 
The deep dermal layer is closed with 2-0 
vicryl suture in an inverted fashion and 
the skin is closed with a 4-0 monocryl 
subcuticular suture, followed by skin glue 
and a sterile dressing.
Technique – CT/Stealth Image 
Guidance
After administration of general endo-
tracheal anesthesia and placement of 
neuromonitoring leads, the patient is 
positioned prone on a Jackson table 
with careful attention to adequately 
padding pressure points and ensuring 
the abdomen hangs free. The low back 
and lateral pelvic area on the side to be 
fused are prepped and draped according 
to standard protocol. A small incision is 
made over the contralateral posterior 
superior iliac spine (PSIS) with a #10 
blade, and the fascia opened sharply with 
monopolar electrocautery. The pin for 
the Stealth reference frame is advanced 
into the PSIS. The O-arm is then draped 
and brought into the surgical field. After 
confirmation of appropriate anteropos-
terior (AP) and lateral views centered 
over the SI joint to be fused, an intraop-
erative CT is obtained and transmitted 
to the Stealth work station. The O-arm is 
then removed from the field. The passive 
planar probe is used to mark the location 
of the sacral ala on the skin, as well as 
Figure 1. Anatomic Landmarks
Relevant anatomic landmarks as seen on 
a lateral fluoroscopic view
Figure 2. Incision Planning
Incision planning with pins placed along the sacral alae (A) and posterior sacral wall (B).  The 
incision is then created about 3 cm in length along the posterior sacral wall, approximately 1 cm 
below the sacral alae (C).
A B C
Figure 3. Pin Placement 
Pin placement about 1 cm below the sacral ala (A).  Pelvic outlet views are obtained to advance 
the pin parallel to the S1 endplate without breaching the sacral foramina (B).  Pelvic inlet views 
are obtained to ensure that the pin placement is appropriate in the anterior-posterior plane (C).
A B C
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baseline demographic and co-morbid-
ities between the fluoroscopy and CT 
groups, while Table 4 shows complica-
tions between the two groups. Baseline 
demographics were notable for a trend 
towards a higher proportion of females 
and a higher proportion of revision 
surgery in the CT cohort. Complications 
were overall fairly rare and did not reach 
statistical significance between groups. 
There were 5 total complications in the 
fluoroscopy group compared to two in 
the CT cohort. There were 4 combined 
cases of neurologic deficit and pseud-
arthrosis, all of which occurred in the 
fluoroscopy group. Revision procedures 
were required in 5 procedures utilizing 
fluoroscopic guidance, compared to one 
in the CT group.
DISCUSSION
Sacroiliac joint dysfunction is an increas-
ingly-recognized source of low back pain. 
This patient population has historically been 
very difficult to treat, with an extremely high 
burden of cost on both a direct and indirect 
basis, often with frustrating outcomes and 
high rates of persistent disability.3-5 The 
traditional focus of back pain has been 
on diagnosis and managing lumbosacral 
pathology as well as neuropathic pain. 
Sacroiliac evaluation is only more recently 
gaining traction. Given that the SI joint is 
the largest articular surface in the human 
body, with fairly complex biomechanics 
central to force transmission across the 
complicated lumbosacral-pelvic anatomy, 
it is not surprising that this may be another 
source of pain.
Previous estimates of up to 30% of 
chronic back pain being referable to the 
SI joint have been published by numerous 
authors.3-7 Recognition of this pathology 
has been limited in the past by a lack of 
clear diagnostic criteria. With increasing 
focus on this clinical entity, there is starting 
to be more consensus on appropriate 
means of diagnosing SI joint dysfunc-
tion. Patient history will often reveal 
pain in the gluteal region, located in the 
region of the PSIS. This may or may not 
be associated with a radiating component 
down the lower extremity and/or into 
the hip and groin. Pain is often worse in 
the sitting position. Physical examination 
is typically notable for positive findings 
on the Fortin’s Finger test, as well as 
were revision procedures. Forty-six proce-
dures were performed utilizing fluoroscopy, 
while 24 utilized CT with Stealth navigation. 
Complications for the entire cohort are 
demonstrated in Table 2. There was a total 
of 7 complications noted: 2 neurologic 
complications (both S1 radiculopathies), 
two cases of pseudarthrosis, 2 hema-
tomas, and one washout that revealed 
only “thickened subfascial tissue”. Overall 
7 patients underwent revision surgery. 
Table 3 shows comparisons in terms of 
RESULTS
A total of 70 procedures were performed 
on 67 patients. Baseline characteristics 
and demographics are shown in Table 1. 
The average age was 50.4, with a male: 
female ratio of 49:21. BMI averaged 30.2. 
Co-morbidities of interest included 9 
patients with diabetes, 13 with lumbosacral 
scoliosis, 5 with confirmed osteoporosis, 29 
with a history of smoking, 5 active smokers, 
and 37 with prior lumbar surgery. Follow-
up averaged 7.6 months. A total of 5 cases 
Figure 4. Implant Placement
On pelvic outlet views, the drill is advanced over the pin (A), followed by broach placement 










large prospective, randomized controlled 
trials (RCT) have been published lending 
further support to the benefit of SI joint 
fusion in carefully selected patients. Polly 
et al20,21 performed an industry-spon-
sored trial of minimally invasive SI fusion 
compared to best medical management. 
A total of 148 patients were randomized 
(102 to SI fusion, 46 non-surgical). The 
primary endpoint was pain as measured 
by VAS, with secondary endpoints 
including disability on ODI, health-related 
quality of life on the EuroQol-5D (EQ5D) 
and Short Form 36 (SF 36). At 24-month 
follow-up, VAS improved from 82.3 to 
26.7 in the surgical group, compared 
to 82.2 to 70.3 in the non-surgical 
group. Similar disparity was noted on 
ODI, EQ5D, and SF-36. At the 6-month 
time point crossover was allowed, and 
39/44 patients in the non-surgical group 
elected for surgery and enjoyed similar 
benefit as those originally randomized 
to surgery. Overall complication rates 
were not significantly different between 
groups. Dengler et al8 performed a 
prospective randomized trial, again 
industry sponsored, that randomized 
103 patients to minimally invasive fusion 
(n=52) or conservative therapy (n=51). 
The primary endpoint was back pain on 
the VAS scale, with secondary endpoints 
including leg pain VAS, ODI, EQ-5D, 
and SI joint function via straight leg 
raise. At 12-month follow-up there was 
significant benefit of surgery compared 
to conservative management across all 
of these measures. Again, crossover was 
allowed at 6 months. Crossover rates 
were high, and benefits were similar to 
those originally randomized to surgery. 
The authors documented 6 procedure-
related complications, of which two 
required revision surgery.
The focus of this study was complica-
tion avoidance and safety. This has 
been explored by previous authors, 
but to our knowledge no data is avail-
able comparing fluoroscopic versus 
CT -based techniques. Schoell et al18 
performed the largest evaluation of 
safety for SI fusion, reporting compli-
cation rates in a minimally-invasive SI 
joint fusion patient population. They 
used CPT and ICD-9 codes to iden-
tify primary (non-revision) minimally 
invasive SI fusion procedures in a large 
nationwide insurance database. They 
patient pain by at least 50-60% prior to 
considering surgical fusion of the joint. 
Therapeutic injections with steroid can be 
used to try to provide longer lasting relief.
Evidence in favor of minimally invasive 
SI joint fusion has largely been limited to 
retrospective studies or smaller prospec-
tive cohort studies.8-11,14-17 Recently two 
reproduction of pain in at least three of 
five provocative SI joint testing maneuvers 
including pelvic distraction, thigh thrust, 
direct compression, flexion/abduction/
external rotation (FABER), and Gaenslen’s 
maneuver. Intrarticular SI joint injections 
with local anesthetic are used to confirm 
the diagnosis. Diagnostic injections relieve 
Figure 6.  Implant Planning 
Implant planning using the Stealth workstation).
Figure 5.  CT/Stealth Setup 
A navigation pin is advanced into the contralateral PSIS and an intraoperative CT scan is 
obtained (A).  The navigated drill guide can then be advanced to the level of the ilium after 
an appropriate incision has been made, and implant planning can proceed (B).
A B
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identified a total of 469 patients and 
noted an overall complication rate of 
13.2% within 90 days, and 16.4% within 
6 months. Notable complications at 90 
days and 6 months respectively included 
new lumbar pathology (3.6% and 5.3%), 
infection (3.6% and 4.1%) “nervous 
system” complications (4.3% and 6.2%), 
and chronic pain (2.6% and 4.1%). These 
rates of complications are somewhat 
higher than compared to previously 
published RCT and prospective cohort 
studies, particularly in regard to infection 
with has often been quoted around 1% 
for minimally invasive SI fusion.8-11,14-
17,20,21 Review of our complication data 
confirms the safety of the procedure, 
with an overall complication rate of 10% 
at mean follow-up of 7.6 months. Of note, 
we had no cases of infection. There were 
3 washouts performed (2 hematoma, one 
which noted only “thickened subfascial 
tissue”). Our transition to O-arm image 
guidance appears to have had a posi-
tive impact on the complication profile, 
although the overall low patient numbers 
and complication rate has prevented 
this difference from reaching statistical 
significance as yet. Of particular interest 
to this study was our rate of neurologic 
deficit and symptomatic pseudarthrosis; 
two cases of each occurred, both in the 
fluoroscopic group. While rare, when such 
complications occur, they almost invariably 
result in revision surgery with possible long-
term implications for patient outcome. 
Proper implant placement is critical to 
avoiding such complications and should be 
improved with more precise image guid-
ance. While fluoroscopy is a useful adjunct 
in this regard, the need for sophisticated 
understanding of sacro-pelvic anatomy on 
pelvic inlet, pelvic outlet, lateral, and other 
views can present a steep learning curve. 
Revision surgery and transitional anatomy 
can make the procedure more difficult, 
even in very experienced hands. Three-
dimensional image guidance such as CT 
with Stealth navigation is helpful in this 
regard, and the lack of implant misplace-
ment in our cohort of 24 navigated cases, 
even with a significantly higher proportion 
of revision cases in this group, is a testa-
ment to that. An additional consideration 
in terms of complications and safety worth 
mentioning is successful fusion across the 
joint. Our study is limited in that we do not 
have routine post-operative References 






This table demonstrates complication profiles for the entire cohort.










Prior Lumbar Surgery 37
Fluoro:Nav 46:24:00
Baseline demographics and co-morbidities for patients undergoing SI fusion.
Figure 7.  Post-Operative Imaging 
Postoperative AP and lateral films showing final implant placement
A B
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CT scans to evaluate bony bridging across 
the SI joint. Previous studies have quoted 
fusion rates at 1-2 years postoperative in 
the range of 80-97%.15,17,19 Two of our 
patients had documented symptomatic 
pseudarthrosis requiring revision, both in 
the fluoroscopy group. However, overall 
statements regarding solid fusion across 
the SI joint are difficult to generate with 
our data given the lack of protocolized 
follow-up CT imaging.
This study has limitations. Most notable 
is the retrospective nature of the analysis, 
and relatively low patient numbers. 
Furthermore, the duration of follow-up 
in this cohort is short, and longer-term 
follow-up would be helpful. Fusion across 
the SI joint was difficult to assess, and a 
standardized protocol for post-operative 
CT imaging to formally evaluate this 
would be helpful to get a better under-
standing of pseudarthrosis rates.
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Table 3.  Baseline Characteristics Between Groups
Fluoro (n=46) CT (n=24) P-Value
Age 50.6 49.9 *
M:F 17:29 4:20 0.078
BMI 30.5 29.5 *
Diabetes 5 4 *
Scoliosis 9 4 *
Osteoporosis 4 1 *
Prior Smoker 18 11 *
Current Smoker 4 1 *
Revision 1 4 <0.05
Prior Lumbar Surgery 24 13 *
This table demonstrates baseline characteristics and comorbidities between the two groups.  * 
denotes a p-value > 0.1.
Table 4.  Baseline Characteristics Between Groups
Fluoro (n=46) CT (n=24) P-Value
Sacral radiculopathy 2 0 *
Pseudoarthrosis 2 0 *
Other 1 2 *
Revision 5 2 *
This table demonstrates complication profiles for both groups. * denotes a p-value > 0.1.
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The care and treatment of spinal cord injury (SCI) patients has significantly evolved 
over the last several decades. There has been great interest and promising research 
conducted over this period resulting in advancement of our understanding of the 
pathophysiology of SCI on both a biochemical and biomolecular level. Concur-
rently, there has also been rapid clinical advancements in treating spinal fractures 
with improvement in the understanding of the biomechanics of injuries, as well as 
improvements in spinal fixation techniques and devices. In addition, there have been 
great strides made in the collaborative care and treatment efforts of SCI patients 
particularly in the fields of radiology, rehabilitation, trauma, and intensive care.
The developments in SCI treatment have led to a decrease in the overall incidence 
of traumatic injuries, particularly in the younger populations. This is mainly a result 
of preventative measures and education by the various foundations who focus on 
the treatment of SCI patients such as CSRS, ASIA, AAOS, CNS, and AANS. In addition, 
there has been a greater emphasis in society on limiting catastrophic injuries such as 
through the use of: airbag immobilization in motor vehicles, helmets, and the overall 
reduction of high-risk activities.
To provide some background information on the pathophysiology of a traumatic SCI, 
it is believed that SCI is multifaceted, with the initial force or compression of the cord 
resulting in the primary injury. This is then followed by an inflammatory or biochemical 
response that results in further injury to the cord over the subsequent days to weeks. 
This is referred to as the secondary injury, and it is this stage of injury that has been the 
target of intense research. Currently, there exists multiple novel strategies in dealing with 
this secondary injury component including surgical techniques, medical management, 
pharmacology, and cell-based therapies which will be discussed below.
SURGICAL TECHNIQUES
Over the last century, it is been established that early decompression of the spinal 
cord results in improved neurologic outcomes. However, not until the publication of 
the STASCIS study (PLoSOne. 2013 Aug 23;8(8):e72659) has clinical data significantly 
demonstrated that early decompression does, indeed, improve neurological outcome. 
This study, in which Jefferson Health was the highest enrolled center, showed that 
surgical decompression and stabilization in less than 24 hours gave the patient the 
greatest chance of improving by up to two neurologic grades in the ASIA scale.
Another area of exciting research has been the use of a biocompatible scaffold poly-
mers for acute spinal cord injury, which is also an option for patients at Jefferson 
Health. This scaffold is surgically inserted into the spinal cord at the site of injury and 
will break down over several weeks. It is postulated that this polymer modulates the 
healing environment in acute injury and provides the structural support in both acute 
and chronic injury necessary to promote a local environment supportive of cell survival 
and growth within the spinal cord. The INSPIRE trial, a study from InVivo therapeutics 
(http://www.invivotherapeutics.com) examined the potential benefit of this Neuro-
Spinal Scaffold (TM) for safety and neurologic recovery in patients with complete 
thoracic (T2-T12) spinal cord injury. This 
study is currently being analyzed and 
there appears to be a neurologic benefit 
with use of this polymer scaffold. Larger 
and more comprehensive studies will 
likely take place following final analysis 
of the data from this trial. 
MEDICAL MANAGEMENT
The medical intensive care treatment of 
the patients after their traumatic SCI is also 
extremely important in overall recovery 
and prognosis. It has been determined 
throughout the last several decades that 
increased blood flow to the spinal cord 
by maintaining patients with an elevated 
mean arterial pressure significantly 
improves neurologic recovery. This is 
akin to elevating the blood pressure in an 
acute stroke patient so as to perfuse the 
brain penumbra that has not yet reached 
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1 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, 19107 
2  Department of Neurological Surgery, Sidney Kimmel Medical College, Thomas Jefferson 
University, Philadelphia, PA 19107
Spinal Cord Injury: Current and Novel 
Treatment Strategies
Figure 1.
Sagittal T2-weighted MRI demonstrating 
post spinal cord injury with increased 
signal and edema within the cervical 
cord (arrow) along with superimposed 
cervical stenosis
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oligodendrocytes, which function to 
provide support and myelin production 
in the central nervous system.
In another trial, named the StemCell Inc 
trial, HuCNS stem cells were implanted 
through direct spinal cord parenchymal 
injections within one year of the injury. 
Despite showing promising improvements 
in neurologic recovery, the study was 
unfortunately halted due to financial issues.
Currently, there is an active trial investi-
gating the use of Schwann cell transplants 
being performed at the University of 
Miami. This study uses Schwann cells 
harvested from the patient and transfers 
them directly into spinal cord injury site. 
The results of the phase 1 portion of this 
trial were published in 2017 and showed 
the safety of this treatment, noting that 
there were no adverse events or serious 
adverse events related to the cell therapy.
It is important to realize, however, that 
that with any new treatment, there can 
be significant complications. Particularly 
related to cell-based therapies, such as 
implantation of stem cells, there is the 
possibility for inducing aberrant growth of 
non-spinal cord tissue which has potential 
to harm the surrounding neural structures.
by blocking the rho activation system. In 
the initial phase 1 study, which compared 
the medication to case controls, not 
only was the medication safe, but it also 
showed to be efficacy. Unfortunately, 
when the medication was compared 
to placebo there was no significant 
improvement, so the trial was ultimately 
halted. However, the study did result in 
greater interest in the investigation of 
drugs to treat and modulate injuries to 
the spinal cord.
CELL-BASED THERAPIES
There is a good deal of excitement about 
the possibility of cell mediated interven-
tions being used to improve neurologic 
outcomes after SCI. We are very fortu-
nate at Jefferson to have been asked to 
participate in many studies investigating 
this topic and strategy. The first stem cell 
spinal cord injury trials were performed 
by Geron Corporation, although, they 
were eventually halted and sold to 
a secondary company that became 
known as Asterias (https://asteriasbio-
therapeutics.com). Asterias has been a 
proponent of intraparenchymal spinal 
cord injection of stem cells. Unlike some 
other cell-based strategies, these do not 
target the neurons directly but rather the 
terminal ischemia. In addition, there is 
interest in the use of hypothermia to 
decrease the metabolic bands of the spinal 
cord during the acute phase of injury to 
help aid in recovery. Jefferson is currently 
involved in this study through a grant from 
the Department of Defense.
PHARMACOLOGY
The largest international SCI pharma-
cological multicentered prospective 
randomized controlled study is presently 
being run through the AO Foundation. 
Jefferson is currently the largest clinical 
enrolling site in North America. This study 
is investigating the drug, Riluzole, which 
is approved for patients with ALS, and its 
effect on reducing excitatory apoptosis 
(cell-initiated death) after an injury to the 
spinal cord. This is a continuation of a 
phase 1 study, also done at Jefferson, 
which showed safety of the medication.
Unfortunately, not all promising initial 
studies are confirmed during their phase 
3 trials. Recently, Jefferson was involved 
with the Vertex SCI trial which examined 
a medication to prevent cell apoptosis 
Figure 3.
(Left) Sagittal T2-weighted MRI and (Right) CT scan demonstrating a thoracic flexion-
distraction injury (fracture dislocation) causing severe spinal cord compression
Figure 2.
Intraoperative lateral radiograph 
demonstrating post-surgical instrumented 
posterior cervical fusion hardware
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Although the overall incidence of 
spinal cord injury is decreasing in our 
population, it is still a major public 
health concern. The costs associated 
with treating and caring for patients 
with spinal cord injuries is quite signifi-
cant. Currently, there is no “cure” that 
exists which allows the spinal cord to 
regenerate and heal completely after a 
traumatic injury, making many of these 
injuries devastating to the patients 
and their families. However, with 
advancements in surgical, medical, and 
pharmacological research coming to 
fruition at a rapid pace, the outlook on 
evolving the care of these patients and 
their injuries is promising.
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ABSTRACT
Arthroplasty is an established treatment for single and multiple level cervical disc 
disease. Multiple contiguous arthroplasties introduce unique changes in spinal kine-
matics that warrant study independent of single-level surgery. The literature regarding 
the biomechanics, indications, outcomes and complications specific to multiple level 
arthroplasties was reviewed. Appropriate application of this technology has been 
shown to be a safe and potentially advantageous alternative to arthrodesis.
INTRODUCTION
Cervical disc arthroplasty (CDA) is an alternative to anterior cervical discectomy and 
fusion (ACDF) for the treatment of cervical disc disease. Developed with the intention 
of preserving or restoring motion of a degenerated disc, CDA has been proposed to 
reduce rates of adjacent segment degeneration and disease.1-4
A single-level ACDF reduces the cervical range of motion approximately 7 degrees, 
while CDA preserves or may even increase motion at that segment.5-10 The benefit 
of replicating physiologic motion to prevent adjacent segment disease has been the 
subject of debate, with several current meta-analyses advocating the use of CDA over 
ACDF for single level disease for this reason.11-13 Evidence includes a randomized control 
trial reporting a significant decrease in the rate of subsequent surgery at 7 years follow 
up for single level CDA compared to ACDF.14
The generalizability of these data to multilevel disease is unclear. Inclusion criteria for 
many randomized controlled trials excluded multilevel treatments or, if multilevel CDA 
was included, those data were often not analyzed independently of single-level results. 
The purpose of this review is to examine the unique considerations and literature of 
multilevel CDA.
BIOMECHANICS
Adjacent segment disease (ASD), defined by Hilibrand as new and symptomatic degen-
erative changes after fusion,15 has been attributed to compensatory biomechanical 
stresses at levels above and below a fusion,16 which approximately 25% of patients who 
undergo ACDF will experience within 10 years from surgery.17 Most biomechanical 
studies on multilevel CDA were designed to investigate this phenomenon.
The degree of additional stress at adjacent levels is commonly quantified by measure-
ments of intradiscal pressure and mobility.16,18 In multilevel ACDF, adjacent discal 
pressures have been shown to increase by 3-6.7 fold, while CDA either maintains or 
even decreases adjacent level pressures.19-22
In a cadaveric load-control study, Phillips found that a single CDA at C5/6 increased 
flexion-extension of that motion segment by 4 degrees but did not significantly change 
rotation or lateral bending. The adjacent segments’ motions were unchanged. Upon 
implanting a second CDA at C6/7, lateral bending of the superior adjacent level (C4/5) 
increased. A single CDA at C6/7 did not reproduce the increase in flexion-extension 
or adjacent level mobility. This suggests 
that multilevel arthroplasty introduces 
unique spinal kinematics and that the 
effects may be level-dependent. In vivo, 
multilevel arthroplasty has demonstrated 
no significant difference from pre-oper-
ative motion at the operated levels.23, 24
Authors have proposed that biomechanical 
stresses are additive with consecutive levels 
of arthrodesis due to increased constraint 
and suggest that arthroplasty may help 
defray the mechanical disadvantages of 
a multilevel fusion;16 however, a recent 
meta-analysis reported that the highest 
prevalence of ASD was in single level 
ACDF, significantly more than in multilevel 
fusion.25 This contradicts finite element 
analyses wherein longer segment ante-
rior fusions have been shown to increase 
adjacent level intradiscal stresses.26 While 
the authors of the meta-analysis suggest 
that multilevel procedures might have 
already addressed the most at-risk levels, 
the etiologies of ASD and how the biome-
chanics of arthroplasty affect them have 
not been fully reconciled with clinical data.
INDICATIONS/PATIENT 
SELECTION
Multiple devices have FDA approval for 
single and multilevel cervical disc arthro-
plasty. Randomized controlled trials 
on multilevel arthroplasty selected for 
patients with degenerative disc disease 
causing radiculopathy or myelopathy 
and excluded patients with pathology 
outside of C3-7.23, 24, 27 Expanded indi-
cations have been reported, including 
acute traumatic disc herniations28 and 
use in upper thoracic levels.29
Contraindications include less than three 
millimeters of available disc space to avoid 
excessive loading of the posterior elements 
by overdistracting anteriorly.30 Kyphotic 
deformity of greater than 15 degrees may 
indicate concomitant posterior element 
pathology that could be exacerbated by 
increasing motion at that segment. Other 
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contraindications include active infection, 
malignancy, and metabolic or inflamma-
tory spine diseases. Osteoporosis may 
increase the risk for implant migration.31
CASE EXAMPLE
A 45-year-old Caucasian male presented 
with eight months of neck pain with radia-
tion down his right arm to his right thumb, 
index and middle finger. There was no 
inciting event or trauma. He was neuro-
logically intact other than a right Spurling’s 
sign. There was no clinical evidence of 
myelopathy.
On review of his cervical MRI, he had 
advanced spondylosis with right greater 
than left neural foraminal narrowing at 
C5-6. Spondylosis with bilateral foraminal 
narrowing was also noted at C6-7. (Figure 1)
He was treated with several weeks of phys-
ical therapy, cervical traction, and three 
epidural steroid injections without lasting 
improvement in his symptoms. Given his 
failure of conservative treatment, surgical 
decompression was recommended. The 
options of arthrodesis and arthroplasty 
were offered to the patient, who elected 
to undergo C5/6 and C6/7 arthroplasties.
Post-operatively, he recovered very well 
with complete resolution of his preopera-
tive neck and arm symptoms. Radiographs 
confirmed adequate cervical alignment 
and device placement. (Figure 2) By 8 
weeks post-op, he had returned to work 
without restrictions as an electrician.
OUTCOMES
Initial trials excluded multiple level 
arthroplasties or combined them with 
single level treatments in their analyses. 
In 2007, Pimenta reported that 2 or 3 level 
CDA experienced significantly greater 
improvements in patient outcomes — 
Neck Disability Index (NDI) and Visual 
Analogue Score (VAS) — than single level 
arthroplasty at 3 years from surgery.32 
Subsequent studies addressed multilevel 
disease independently.
One class-one randomized, controlled trial 
has been published comparing patients 
who underwent single and multiple-
level CDA. Clinical outcome scores 
were not significantly different between 
the two arms: both groups had similar 
NDI, VAS, Short Form 12 (SF-12 MCS/
Figure 2.
Sagittal T2 MRI showing multi-level spondylotic changes without disc space collapse 
or kyphotic deformity (A).  Axial MRI through the C5/6 (B) and C6/7 (C) disc spaces 
demonstrating broad based disc bulging that results in right foraminal stenosis at C5/6 and 
bilateral foraminal stenosis at C6/7.
Figure 1.
Post-operative lateral (A) and anterior/posterior (B) radiographs showing stable cervical 
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large prospective trials on multiple level 
arthroplasties, only one case of migra-
tion was reported in a study of 255 
patients with 4 years of follow-up.23
Sagittal fracture while preparing superior 
and inferior keels in a single vertebra is 
a unique complication of subsequent 
level arthroplasty. The few case reports 
available suggest that this is a rare 
phenomenon and may be managed with 
a rigid cervical collar, though prolonged 
post-operative pain may occur.42
CONCLUSION
Multilevel CDA has demonstrated unique 
biomechanics and complication profiles 
compared to arthrodesis and single-level 
arthroplasty. Multilevel arthroplasty 
offers advantages in patient-reported 
outcome measures to arthrodesis in 
appropriately selected patients.
REFERENCES
1. Lafuente J, Casey AT, Petzold A, Brew S. The 
Bryan cervical disc prosthesis as an alterna-
tive to arthrodesis in the treatment of cervical 
spondylosis: 46 consecutive cases. J Bone 
Joint Surg Br. 2005;87:508-12.
2. Lin EL, Wang JC. Total disk arthroplasty. J Am 
Acad Orthop Surg. 2006;14:705-14.
3. Shim CS, Lee SH, Park HJ, Kang HS, Hwang 
JH. Early clinical and radiologic outcomes 
of cervical arthroplasty with Bryan Cervical 
Disc prosthesis. J Spinal Disord Tech. 
2006;19:465-70.
4. Yoon DH, Yi S, Shin HC, Kim KN, Kim SH. 
Clinical and radiological results following 
cervical arthroplasty. Acta Neurochir (Wien). 
2006;148:943-50.
5. Heller JG, Sasso RC, Papadopoulos SM, 
Anderson PA, Fessler RG, Hacker RJ, et al. 
Comparison of BRYAN cervical disc arthro-
plasty with anterior cervical decompression 
and fusion: clinical and radiographic results of 
a randomized, controlled, clinical trial. Spine 
(Phila Pa 1976). 2009;34:101-7.
6. Mummaneni PV, Burkus JK, Haid RW, 
Traynelis VC, Zdeblick TA. Clinical and radio-
graphic analysis of cervical disc arthroplasty 
compared with allograft fusion: a randomized 
controlled clinical trial. J Neurosurg Spine. 
2007;6:198-209.
7. Murrey D, Janssen M, Delamarter R, Goldstein 
J, Zigler J, Tay B, et al. Results of the prospec-
tive, randomized, controlled multicenter 
Food and Drug Administration investigational 
device exemption study of the ProDisc-C 
total disc replacement versus anterior discec-
tomy and fusion for the treatment of 1-level 
symptomatic cervical disc disease. Spine J. 
2009;9:275-86.
three-level anterior cervical plate fixa-
tion was found to cause five-fold higher 
intraesophageal pressures than what is 
required to place equivalent level arthro-
plasties due to increased retraction.34 A 
prospective, randomized trial showed 
a decrease in dysphagia on the Bazaz-
Yoo scale with zero-profile arthroplasty 
compared to arthrodesis with plate fixa-
tion.35 The etiology of the dysphagia may 
be attributable to the increased dissec-
tion and retraction required to introduce 
the plate or from the presence of a 
foreign body within the retropharyngeal 
space. Consecutive interbody fixation 
devices without an anterior plate may 
obviate this benefit of arthroplasty.
Heterotopic ossification (HO) is a 
common complication of prosthetic 
joints, wherein new bony growth may 
inhibit movement of the prosthesis 
or cause compression of the neural 
elements. The McAfee classification 
divides HO of CDA into grades I/II, 
which comprise radiographic findings 
of bony growth and grades III/IV, which 
have clinical manifestations of limited 
movement.36 The pooled prevalence of 
HO in single and multilevel CDA across 
multiple studies has been reported as 
58.2% at 2 years, with a 16.7% rate of 
grade III or above.37 Wu reported higher 
rates of HO in two-level arthroplasty 
(75.0%) compared to single level (40.5%), 
with 14.3% of arthroplasties losing their 
mobility after multilevel surgery.38 In 
prospective trials of two-level arthro-
plasty, rates of clinically significant HO 
were 16.6% 23 and 29.7%.24 Arthroplasties 
at C3/4 may also have higher levels of HO 
due to decreased physiologic motion at 
that level compared to the other subaxial 
segments.39
Implant migration is a rare complication 
of CDA that may produce iatrogenic 
injury. The largest report of symptom-
atic migrations comprised 5 patients 
who underwent single or multiple-level 
CDA in a single institution, with an overall 
rate of 0.4% of all cervical arthroplasties 
performed.40 In four cases, the device 
was explanted and revised with ACDF 
and in one patient, the implant was 
simply removed. Zhai reported a case 
of migration in a two-level arthroplasty 
that presented with dysphagia and was 
revised with a corpectomy of the middle 
vertebra and multilevel fusion.41 Of the 
PCS), and satisfaction scores. The rate of 
complications, subsequent surgeries, and 
heterotopic ossification were also not 
significantly different.27 
In a systematic review, Joaquim identified 
two class-one randomized, controlled 
trials that compared contiguous multi-
level arthroplasties against arthrodesis.33 
In a 330 patient study, Davis found posi-
tive patient-reported outcomes with CDA: 
a significant decrease in NDI and SF-12 
PCS that was maintained for 4 years of 
follow up and improved patient satisfac-
tion scores. Neck pain and arm pain VAS 
scores were not significantly different, 
though neck pain scores were transiently 
lower with arthroplasty. ACDF had a 
higher rate of subsequent surgery on the 
index level, 4.0 vs 15.2%, predominantly 
for symptomatic pseudoarthrosis.23
Radcliff conducted a second randomized, 
controlled trial in 325 patients. Similarly, 
NDI and SF-12 PCS were significantly 
lower with arthroplasty at all post-
operative time points through 5 years 
of follow up. There was no difference in 
VAS scores for arm or neck pain. Again, a 
lower probability of subsequent surgery 
on index or adjacent levels was identified 
with arthroplasty. Range of motion was 
not significantly changed from pre-oper-
ative values by CDA. Rates of adjacent 
segment degeneration were assessed by 
the Kellgren-Lawrence scale: CDA had 
significantly less degeneration (50.7%) 
than arthrodesis (90.5%). These two 
studies suggest that ASD is not prevented 
by CDA, but patients with multilevel 
arthroplasty may develop radiographic 
changes and become symptomatic at 
a slower rate than those with multilevel 
ACDF for at least five years.24
COMPLICATIONS
Anterior cervical arthroplasty and 
arthrodesis share a similar complication 
profile due to their common surgical 
approach. Xu conducted a systematic 
review of arthroplasty trials and reported 
dysphagia/dysphonia at rates of 1.3 to 
27.2%, vascular injury including hema-
toma at 1.1 to 2.4%, dural injury at 0.0 to 
7.1%, and wound infection at 1.2 to 22.5%.
Dysphagia is a well-described approach-
related complication to anterior cervical 
surgery. In a cadaver model, placing 
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ABSTRACT
Bone-sparing techniques for transforaminal lumbar interbody fusion (TLIF) are 
promoted to help maintain spinal stability and to minimize operative time. We present 
a series of seven patients who underwent TLIF with use of an interbody expandable 
mesh device and with supplemental instrumentation. This device is deployed and filled 
with bone through a small cannula. All patients experienced pain relief and suffered no 
complications. Our results support the data from other centers which have performed 
similar procedures with this device. 
Keywords: transforaminal lumbar interbody fusion, OptiMesh, deployable mesh, 
minimal access
INTRODUCTION
Lumbar interbody devices can be difficult to insert from a posterior approach due to 
their sizes and shapes, especially when the disc space is significantly collapsed (Figure 
5). In addition, stabilizing posterior elements are removed in order to create a clear 
corridor to the disc space. A less invasive approach to the disc space involves the place-
ment of a collapsed, expandable mesh pouch (OptiMesh by Spineology, St. Paul, MN). 
The pouch is gradually filled with increasing amounts of allograft bone chips through 
the small portal. (Figure 1) The mesh itself is made out of polyethylene terephthalate, a 
non-absorbable and pliable material commonly used in vascular grafts. We describe a 
series of patients who underwent this procedure with supplemental instrumentation.
Spineology OptiMesh graft containment system has been approved for the treatment 
of stable vertebral body defects. The device has also been used in the disc space 
for interbody fusion.2,5,6,7,8,9 The OptiMesh portal, despite its low profile, allows for 
an extensive discectomy and with preparation of the endplates, especially when the 
cannulas are introduced bilaterally. The 
bone chips are packed into the mesh 
until good filling of the disc space is 
noted on fluoroscopic imaging.
CASE PRESENTATIONS
From August 2016 through January 2019, 
seven patients underwent lumbar trans-
foraminal interbody fusions by the senior 
author using the mesh containment 
device with supplemental instrumenta-
tion, either interspinous clamps (Patients 
2, 3 and 5) or bilateral pedicle screws/rods 
(Patients 1,4,6 and 7). Five patients had 
the interbody device placed with some 
minimal bony removal. Two patients 
had the mesh inserted via a purely 
percutaneous, bone-sparing approach 
via Kambin’s triangle (Figures 2 and 3).4 
We utilized neuromonitoring for the 
percutaneous approaches.
Patient 1 was a 66-year-old female who 
presented with five years of low back pain 
and one year of right lower extremity 
pain. An MRI revealed retrolisthesis of L2 
on L3, which had progressed slightly over 
seven years. There were stable findings 
of anterolisthesis at L4-5 and at L5-S1.
Patient 2 was a 49-year-old male with 
many years of back pain with one year of 
paresthesias and numbness in the bilat-
eral lower extremities. An MRI showed 
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Table 1. 
Patient Info TLIF level, type Follow up Outcome Compared to Pre-op
1. 66 yo F L2-3 open 29 months 90% overall pain relief
2. 49 yo M L3-4 open 24 months 95% overall pain relief
3. 73 yo F L1-2 open 18 months 90-95% overall pain relief
4. 66 yo M L4-5 open 17 months 80-85% overall pain relief
5. 42 yo M L5-S1 open 5 months 50% overall pain relief
6. 57 yo F L4-5 percutaneous 3 months 95% overall pain relief










regained her strength and sensation 
but her preoperative, chronic low back 
pain and left lower extremity pain had 
worsened after the procedure. An MRI 
revealed very severe degenerative disc 
disease at L1-2 with Modic changes. Also 
noted were postoperative changes at L4 
to S1.
Patient 4 was a 66-year-old male with 
chronic lower back pain which had 
worsened over six months. He also 
complained of bilateral lower extremity 
weakness when going up or down stairs. 
Physical exam revealed no objective 
weakness. An MRI revealed a grade I 
spondylolisthesis at L4-5 with Modic 
changes and moderate central stenosis.
Patient 5 was a 42-year-old male with 
a history of end-stage renal disease 
and had presented to the hospital 
with severe, intractable low back pain 
radiating into the left lower extremity. 
An MRI showed evidence of a discitis 
at L5-S1 and cultures from a needle 
biopsy by interventional radiology grew 
Staphylococcus epidermidis. Despite 
initial antibiotic treatment and narcotic 
medications, he remained in severe 
intractable pain. He did have a history of 
chronic low back pain.
Patient 6 was a 57-year-old female who 
had undergone a right hemilaminectomy 
and bilateral sublaminar decompression 
at L4-5. She continued to have bilateral 
lower extremity pain two months after 
surgery, and dynamic radiographs had 
demonstrated abnormal motion at L4-5.
Patient 7 was a 46-year-old male who 
had undergone an L5-S1 instrumented 
interbody fusion nine years ago. He 
had developed progressive low back 
and bilateral lower extremity pain, left 
greater than right. An MRI showed some 
mild degenerative disc disease at L4-5 
but dynamic radiographs revealed insta-
bility at this level with a solid fusion at 
L5-S1. This particular patient required 
revision of his existing hardware in order 
to couple it to the new pedicle screws 
which were inserted into L4. However, 
the interbody mesh was delivered via an 
entirely percutaneous approach.
All patients experienced pain relief 
compared to preoperatively with no 
complications (nerve root injuries, duroto-
mies, infections, or hardware failures). All 
Patient 3 was a 73-year-old female who 
had undergone an emergent lami-
nectomy at an outside institution for 
sudden-onset bilateral lower extremity 
weakness three months earlier. She 
a moderate left-sided L3-4 disc/osteo-
phyte complex with severe degenerative 
collapse and Modic changes. Similar 
findings, to a lesser degree, were seen 
at L5-S1.
Figure 2 and 3.
Intraoperative fluoroscopic images on patient number 7 show the percutaneous 
instrumentation being placed into the bilateral disc spaces via Kambin’s triangle.  
The disc is removed and the endplates prepared.  The OptiMesh is then introduced 
and filled gradually with granular bone graft.
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the shape of the actual disc space. The 
PEEK or metal used in most interbody 
devices also occupy significant space, 
whereas the mesh allows for more 
surface area contact for bone to remodel 
Various expandable interbody cages are 
available, but most devices expand only 
in the sagittal plane, not in the axial and 
coronal ones. The OptiMesh expands in 
all planes and, as mentioned, contours to 
patients, except for number 5, had failed 
conservative management including 
physical therapy and/or epidural steroid 




In order to place a typical interbody 
cage via a TLIF, the unilateral facet joint 
is generally removed in its entirety. Stan-
dard TLIF cages measure from 7 mm 
to 16 mm in height with 10 to 11 mm 
width. The Spineology OptiMesh cannula 
measures 7 mm in diameter; all the bone 
chips that fill the mesh are delivered 
through this size portal. The mesh 
allows for much less bony removal and 
also the option of a purely percutaneous 
approach requiring no bony removal via 
a trajectory through Kambin’s triangle.
The rigidity and contour of most inter-
body devices often causes undesired 
trauma to the vertebral endplates during 
insertion. Weakening of the endplates 
could contribute to settling of bone 
over the interbody construct. The mesh 
appears to conform well to a patient’s 
unique endplate shape and integrity 
(Figure 7). Moreover, the density of 
the inserted bone chips should more 
closely match that of a patient’s own 
bone than polyetheretherketone (PEEK) 
or metal, theoretically reducing the risk 
of subsidence.
Figure 4.
Postoperative CT on patient number 7 show the interbody graft in good position at L4-5.  
The previous L5-S1 interbody fusion is also seen. 
Figure 6.
Postoperative CT on patient number 4.  
The placement of the interbody graft is in 
the anterior disc space and the lordosis 
is maintained.  Such placement of a 
graft would be difficult to achieve from 
a posterior approach with a traditional 
interbody device due to the narrow entry 
point through the dorsal disc space. 
Lordotic cages have a leading edge which 
are larger than the tail end.
Figure 5.
Preoperative CT on patient number 
4.  Arrow points to narrow corridor for 
insertion of a TLIF cage.
Figure 7.
Postoperative CT scan on patient number 
6 shows the mottled appearance of the 
endplates with the OptiMesh device 
within the disc space.  The unhealthy 
endplates make placement of a very rigid 
device undesirable. 
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and potentially increase the likelihood of 
a robust bony fusion. 
Based on our limited experience, the 
mesh device is a safe, effective option for 
TLIF. Its main advantages appear to be 
decreased anatomical disruption during 
delivery and deployment, the ability to 
expand in all planes with conformity to 
the endplates, and greater surface area 
contact of bone for remodeling and 
fusion. A study involving a larger number 
of patients and further long-term follow 
up is warranted.
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INTRODUCTION
Low back pain (LBP) is a pervasive problem impacting health systems across the world. 
In the United States, chronic LBP impacts up to 40% of Americans and results in exces-
sive financial strain on the healthcare budget, estimated at up to $100 billion annually.1 
Furthermore, treatment results are often disappointing, with the traditional pathway of 
conservative measures, narcotic pain medication, and surgical decompression and/or 
fusion leading to both patient and provider frustration, complications, and diminished 
patient productivity and quality of life. This has naturally led to questions from policy-
makers regarding the utility of healthcare dollars spent on back pain. In this milieu, a 
variety of neuromodulation techniques have found a niche in the management of this 
patient population, with indications commonly quoted including failed back surgery 
syndrome (FBSS), chronic neuropathic pain, and complex regional pain syndrome 
(CRPS), among others.1,2 From its inception on the basis of Melzak and Wall’s gate 
theory³, to its first human trial in the 1960s,⁴ and to the modern era, spinal cord 
stimulation has undergone a series of innovations that have expanded indications and 
improved patient outcomes. The goal of this study is to summarize the most important 
clinical trials involving both traditional SCS and newer stimulation paradigms to provide 
an overview of the current state of affairs of this rapidly-growing field.
METHODS
We performed a PubMed literature search utilizing the following terms: SCS, spinal 
cord stimulation, neuromodulation, high frequency stimulation, paresthesia free, 
HF10, failed back surgery syndrome, and chronic pain. Only English language articles 
were reviewed. All prospective, randomized controlled trials pertaining to the use of 
neuromodulation in the treatment of chronic back and limb pain were included. The 
data extraction was performed by three reviewers (JT, JH, CH), and reviewed by the 
senior author (CW). The selected studies were analyzed, and relevant results were 
summarized as follows.
RESULTS
Traditional, Low Frequency, Tonic SCS
Several landmark trials paved the way for the widespread use of spinal cord stimula-
tion in the treatment of chronic back and limb pain. These early studies utilized low 
frequency stimulation generally in the 40-100 Hz range delivered in a tonic manner, 
producing paresthesias that overlap the areas where the patient experiences pain. 
North et al5 randomized 51 FBSS patients with chronic lower limb pain with or without 
back pain to initial treatment with a low frequency stimulator or re-operation. The 
primary endpoint was “success”, defined as > 50% reported pain relief and patient 
satisfaction with treatment at 2-years post-operatively or at last follow-up. Secondary 
end points included treatment crossover, success at last follow-up, and improve-
ment in medication use, daily activities, and neurologic status. At mean three-year 
follow-up, “success” was achieved in a significantly higher proportion of patients 
randomized to SCS (47%) compared to 
those randomized to reoperation.5,6 
These findings remained statistically 
significant even after worst-case analysis 
which assumed patients unavailable for 
long-term follow-up in the SCS group 
were all treatment failures. Further, a 
significantly higher proportion of patients 
in the reoperation arm crossed over to 
SCS (54%) compared to only 21% of SCS 
patients who elected to undergo reop-
eration. While patient reported functional 
capacity didn’t reach a significant differ-
ence, SCS patients did require significantly 
fewer opiate equivalents for pain control. 
Kumar et al 7,8 followed this up with the 
PROCESS study which randomized 100 
FBSS patients with limb>back pain to 
SCS with medical management (n=52) 
or medical management alone (n=48). 
The primary end point of the study was 
defined as > 50% relief of leg pain, with 
secondary end points including quality 
of life, functional capacity as measured 
by the Oswestry Disability Index (ODI), 
patient satisfaction, and changes in pain 
medication usage. At 6-month follow-
up, the primary endpoint was achieved in 
48% of SCS patients compared to 9% in 
the medical management alone group. 
The SCS group also reported significantly 
greater quality of life, improvement in ODI, 
treatment satisfaction, and reduced back 
pain compared to medical management 
alone. SCS patients were also more likely 
to reduce drug intake based on morphine 
equivalents as well as decrease use of non-
drug therapies. Similar improvements were 
maintained at 12 and 24 month follow-up 
analyses.7,8
Paresthesia-Free SCS
As clinical experience with traditional, 
paresthesia-based systems grew, interest 
began to develop in creating new stimu-
lation protocols that would generate 
pain relief without the need for pares-
thesia overlap as a significant number 
of patients found these sensations to be 
uncomfortable, particularly when there 
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pain compared to baseline, higher likeli-
hood of achieving minimal disability on 
ODI, and higher patient reported treat-
ment satisfaction. Additionally, 11.3% 
of patients in the tSCS group reported 
uncomfortable paresthesias, with no 
patients in the HF10 group reporting any 
paresthesia-related issues.14,15
Despite accumulating clinical evidence 
regarding the efficacy of high frequency 
SCS, several questions remained. One such 
issue is the impact of varying frequencies 
and other stimulation parameters on treat-
ment effect. One study16 prospectively 
randomized a cohort of 24 patients into a 
blinded crossover study, with each patient 
experiencing 3 weeks at a time of sham 
stimulation, and stimulation at 1200 Hz, 
3030 Hz, and 5882 Hz. The devices were 
programmed such that amplitude was 
maintained slightly below threshold level, 
unique to each patient and frequency. 
The primary outcome was the reduction 
of VAS back pain scores. Baseline VAS 
was reported at 7.75, with improvement 
to 4.83, 4.51, 4.57, and 3.22 for the trial 
groups (sham, 1200 Hz, 3030 Hz, and 
5882 Hz, respectively). All comparisons 
to baseline were significant, but within 
the treatment groups only 5882 Hz had a 
significantly greater impact on outcome. 
The authors argued that while designed 
as a study on frequency, the impact of 
pulse width on allowable amplitude 
without generating paresthesia yielded 
higher charger-per-second dosing with 
higher frequency stimulation, which 
may have played a role in the results. 
The results also questioned to what 
degree pain relief afforded by spinal cord 
stimulation is a result of placebo, as at 
the end of the study 12.5% of patients 
preferred the sham stimulation protocol. 
A similar study also explored the impact 
of varying degrees of high-frequency 
stimulation on treatment effect, noting 
the unclear mechanism of HF10 and the 
unclear impact of frequency on clinical 
outcome. In this study, Thomson et al 17 
randomized 21 patients with chronic 
back>leg pain who had passed a trial of 
10 kHz stimulation and were implanted 
with permanent devices. Each patient 
experienced four weeks of stimulation, 
in random order, at 10 kHz, as well as 1-, 
4-, and 7 kHz. At each frequency, pulse 
width and amplitude were adjusted to 
optimize therapy. The impact on the 
patients reverted to their traditional, 
paresthesia-based pattern. The primary 
outcome was the Patient’s Global 
Impression of Change (PGIC), with 
secondary outcomes including VAS 
and the Euroqol questionnaire EQ-5D. 
At the end of the study, the authors 
noted no difference between sham and 
high-frequency stimulation, with what 
appeared to be a “period effect” in that 
patients tended to respond more favor-
ably to sham or 5 kHz stimulation based 
purely on which was initiated first and 
responded less favorably to whichever 
pattern was tested second. However, 
the comparison to baseline values is 
confusing and again the use of previously 
stabilized tSCS patients is a variable that 
must be considered. The most robust 
data in this field came from Kapural and 
colleagues who explored the ability of 
low amplitude, high frequency spinal 
cord stimulation at 10 kHz to provide 
durable relief of both axial and appen-
dicular pain in the SENZA trial.14,15 In this 
prospective, multicenter, randomized trial, 
the investigators randomized 198 patients 
with medically refractory back and leg 
pain to either high frequency stimula-
tion (HF10) or traditional low frequency, 
paresthesia-dependent treatment (tSCS). 
The primary endpoint was >50% reduc-
tion on the visual analog scale (VAS), with 
secondary outcomes including opioid 
use, functional disability as measured by 
ODI, and percentage change from base-
line back and leg symptoms. A total of 
171 patients had positive trials and were 
ultimately implanted (HF10, n=90; tSCS, 
n = 81). At the initial 3-month evalua-
tion, 84.5% of HF10 patients achieved 
the primary endpoint for back pain, 
compared to only 43.8% of tSCS patients. 
Similarly, for leg pain HF10 success on the 
primary endpoint was 83.1% compared 
to 55.5% for tSCS. These values remained 
similar at 12-month follow-up evalua-
tion, with remission rates (VAS <2.5) for 
back and leg pain approaching 67% for 
HF10, compared to 35-40% for tSCS. 
At 24-month evaluation, the difference 
in primary endpoint success was still 
maintained in favor of HF10 for both 
back and leg pain (76.5% and 72.9% 
respectively for HF10, compared to ~50% 
for tSCS). Secondary outcome analysis 
also favored HF10, with greater overall 
percentage reduction of back and leg 
is significant postural variation which 
can make certain daily activities, such 
as driving, difficult or painful. Further-
more, traditional spinal cord stimulation, 
while relatively successful at treating 
appendicular neuropathic symptoms, 
struggled with relief of more nociceptive 
axial pain where adequate paresthesia 
overlap is difficult to achieve. Given how 
common low back pain is in the general 
population, a more efficient means for 
targeting this symptom complex was 
needed. Buyten et al 9 prospectively 
enrolled 82 patients with back pain with 
or without associated leg pain in a trial 
of high frequency, low amplitude, pares-
thesia free stimulation using the Nevro 
device. The outcomes of interest were 
VAS scores, ODI, sleep disturbances per 
night, and patient satisfaction. The trial 
to conversion rate was 88%. VAS back 
and leg scores improved at 6 months, 8.4 
to 2.7 for back and 5.4 to 1.4 for leg pain. 
ODI improved by 17 points and patients 
reported 2.4 fewer episodes of sleep 
disturbance per night. Similar results 
were obtained with HF10 therapy in 
another prospective observational study 
in patients with a primary complaint low 
back pain, with back pain and leg pain 
reduced by 61% and 58%, respectively, 
based on VAS10. While promising, these 
and other observational studies did not 
provide a control group to compare 
against. To that end, De Andres et al11 
compared high frequency (10 kHz) 
stimulation to conventional stimulation, 
randomizing 55 patients with FBSS with 
neuropathic back or leg pain. The results 
suggested no significant difference at 
one year, with both stimulation profiles 
showing significant benefit compared 
to baseline values.11 On the other hand, 
North et al,12 in their pilot study random-
izing patients with FBSS who had a 
previously implanted, paresthesia-based 
system with inadequate pain relief, noted 
that pain relief via NRS and disability 
via ODI were significantly improved 
with 1 kHz stimulation.12 Perruchoud 
and colleagues13 similarly random-
ized patients with chronic neuropathic 
back and leg pain, previously stable on 
a conventional SCS system, to periods 
of sham and 5 kHz, subthreshold tonic 
stimulation. The periods of sham and 
5 kHz stimulation were separated by 
a “washout” period during which the 
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with burst compared to only 2.7% of 
tSCS patients. While 78.1% of patients 
were satisfied overall with both stimula-
tion methods, 70.8% reported preferring 
burst stimulation with lack of paresthesia 
being the most common reason cited. 
This preference was maintained at one-
year follow-up with 68.2% of patients 
continuing to prefer burst therapy. Much 
like high frequency stimulation, as the 
clinical efficacy became clear, more ques-
tions emerged regarding mechanisms and 
the impact of various stimulation param-
eters. One study  21 randomized 15 patients 
previously implanted with a burst-capable 
device in the setting of FBSS to one of two 
stimulation patterns: 1) 5 pulses delivered 
at 500 Hz with a 1000 µsec pulse width, 40 
times per second or 2) 5 pulses delivered at 
1000 Hz, 1000 µsec pulse width, 40 times 
per second. The amplitude, and thus the 
total electrical dose delivered remained 
the same. Clinical outcomes were not 
significantly different.
DISCUSSION
Spinal cord stimulation was first put 
into clinical practice in the 1960s for 
an attempt at palliation in a patient with 
terminal cancer pain.4 The momentum 
behind its initial development was 
the ubiquitous Gate Control Theory 
put forth by Melzack and Wall.3 While 
generally accepted that this theory is 
overly simplistic regarding the mecha-
nism of action in the various spinal 
cord stimulation techniques, it did 
inspire generations of physicians and 
scientists to develop new means of 
tackling medically refractory chronic 
pain syndromes.22 Traditional, low-
frequency, suprathreshold tonic spinal 
cord stimulation has been postulated 
to work via several mechanisms. Most 
commonly cited includes selective 
activation of large, myelinated Aβ fibers 
with subsequent inhibition of smaller, 
pain-mediating Aδ and c fibers via 
inhibitory interneurons. Other postu-
lated contributors include dorsal horn 
wide dynamic range neurons, thought to 
develop a hypersensitivity in neuropathic 
injury states with resultant increased 
basal glutamate release and subsequent 
glutamate:GABA imbalance. Supraspinal 
mechanisms are also thought to be at 
play although the exact brainstem-spinal 
pain was significantly reduced with burst 
therapy (-4.5 VAS) compared to tSCS 
(-2.5). Regarding the PVAQ, tonic and 
placebo stimulation showed no impact 
on attention to pain or attention to 
changes in pain, whereas burst stimulation 
significantly improved these parameters, 
suggesting an impact on affective and 
attentional components of pain. Schu et al 
19 compared high frequency stimulation to 
a burst protocol, randomizing 20 patients 
with FBSS and a previously implanted, 
burst-capable system to separate, one 
week periods of placebo stimulation, 500 
Hz tonic stimulation, and burst stimulation 
(5 pulses at 500 Hz, delivered 40 times 
per second), with the primary outcome 
of interest the impact on the numerical 
rating scale (NRS) for pain intensity. Base-
line values were obtained prior to entering 
the protocol, with the device programmed 
for standard, paresthesia-based stimula-
tion. While burst stimulation was the only 
pattern to significantly reduce the NRS 
score, the magnitude of the treatment 
effect was modest (5.6 at baseline, 4.7 
for burst stimulation), and disability as 
measured by ODI showed only a non-
significant decrease. However, it is worth 
reiterating that the “control” values in this 
study were based on patients stabilized 
on a paresthesia-based system, and thus 
treatment effects can be expected to be 
blunted, and the fact that at the end of 
the trial 80% of the patients preferred the 
burst protocol is also significant. More 
recently, Deer et al20 published results of 
the SUNBURST trial, which randomized 
patients with refractory back and leg pain 
to tSCS or burst stimulation. The trial was 
conducted in two phases. First patients 
were randomized to a 12-week period of 
a given stimulation treatment, and then 
switched to the other stimulation method 
for the next 12 weeks. Thereafter, the 
patients were allowed to choose their 
preferred stimulation method and were 
assessed every 6 months for two years. 
The primary endpoint was change in VAS. 
A total of 100 patients were randomized, 
with 45 entering tSCS first followed 
by burst, and 55 vice versa. At 12- and 
24-week analyses, both non-inferiority 
and superiority of burst stimulation as 
compared to tSCS were established via 
the primary endpoint of VAS reduction. 
Secondary endpoint analyses revealed that 
61.6% of patients were paresthesia-free 
primary outcome, NRS for back, leg, and 
overall pain, was similar between groups 
with all frequency groups showing about 
50% reduction in each category. There 
were no between-group differences. 
There was significantly less charge 
delivered in the 1 kHz stimulation than in 
the other three groups. Interestingly, the 
calculated charge delivered per second 
showed a non-linear relationship with 
frequency, suggesting that frequency 
modification in isolation may not deliver 
appropriate symptom relief, highlighting 
the importance of the interplay between 
frequency, pulse width, and amplitude.
As interest in paresthesia-free stimulation 
grows, other investigators are exploring 
novel stimulation protocols. Burst stimula-
tion, a technique based on short intervals 
of high-frequency, low amplitude stimula-
tion followed by periods of inactivity, is one 
such protocol thought to work in at least 
two mechanisms: 1) more closely mimic 
neuronal firing in the central nervous 
system with impacts on higher-order thal-
amo-cingulate pathways, and 2) provide 
inhibition of Aδ and c fibers via subthreshold 
antidromic Aβ activation with resultant 
activation of inhibitory interneurons. De 
Ridder et al18 performed an early trial with 
this technology, randomizing 15 patients 
undergoing a trial of spinal cord stimulation 
to 7 days each of burst, tonic, and sham 
stimulation. Primary endpoints included 
VAS for back, limb, and general pain, with 
secondary endpoints including the pain 
vigilance and awareness scale (PVAQ), and 
worst/best pain levels during a given trial 
week. They noted that burst stimulation 
did not induce more paresthesias than 
sham stimulation. The primary outcome 
measure showed significant improve-
ments in back, limb, and general pain 
comparing burst stimulation to placebo. 
Because burst stimulation produced no 
noticeable paresthesias, this marked the 
first time in a randomized trial that spinal 
cord stimulation could be proven better 
than control/sham treatment, an important 
landmark in SCS research. Not surprisingly, 
tSCS showed significant improvement in 
limb and general pain, but not back pain, 
compared to placebo. Comparing burst 
to tSCS, the mean change in back pain 
favored burst (-3.8 on VAS compared to 
-2.2), but this did not reach significance. 
Limb pain between the two protocols 
was the same (both -3.9 on VAS). General 
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Modern Spinal Stimulation 
CONCLUSION
Chronic back pain remains a highly prev-
alent clinical problem in modern society. 
This patient population has historically 
been very challenging to treat.  Spinal 
cord stimulation has helped to bridge 
the treatment gap in these patients, and 
while progress so far has been encour-
aging, there remains much research to 
be done to fully understand the mecha-
nisms and potential therapeutic reach of 
this modality.
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circuitry activated by spinal cord stimu-
lation remains largely theoretical.22 
Regardless of the inner workings of 
the therapy, spinal cord stimulation has 
proven to be an important development 
in the management of an otherwise 
frustrating patient population. Medical 
management in chronic pain conditions 
often fails and is associated with high 
rates of narcotic medication use with 
their associated complications. Futile 
treatment regimens, although inex-
pensive in isolation, become expensive 
when applied indefinitely, and costly 
revision surgeries without clearly rectifi-
able structural or compressive pathology 
are not only low yield, but very expensive 
and potentially dangerous. Spinal cord 
stimulation has provided an opportunity 
to attain symptom relief, limit disability, 
and improve patient productivity. And 
although the upfront investment is 
large, there is an increasing amount of 
evidence suggesting that the long-term 
cost-effectiveness profile is positive 
and that spinal cord stimulation should 
be considered earlier in the broader 
treatment paradigm for chronic pain.1,2 
With all of this said, spinal cord stimu-
lation is certainly no panacea. One of 
the most important limiting factors is 
the requirement for a high-degree of 
overlap between induced paresthesia 
and the patient’s baseline pain. This 
becomes a problem for patients that 
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efficient low back coverage is a priority 
for next generation models.
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As a part of the Vickie and Jack Farber Institute for Neuroscience at Jefferson, the Department of Neurological 
Surgery is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to 
patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain 
diseases, epilepsy, pain, Parkinson’s disease and many other neurological disorders (Jefferson.edu/Neurosurgery).
As part of a larger educational initiative from the Jefferson Department of Neurological Surgery, the Sidney Kimmel 
Medical College Office of Continuing Professional Development is offering the following continuing professional 
educational opportunities for 2019:
•  8th Annual Jefferson Neurocritical Care Symposium 
Friday-Saturday, February 22-23, 2019 
Dorrance H. Hamilton Building, Center City Campus  
of Thomas Jefferson University
•  18th Annual Cerebrovascular Update 
Thursday-Friday, March 14-15, 2019 
The Bellevue, Philadelphia, PA
•  5th Annual Philadelphia Spine Summit  
Friday, May 10, 2019 
Dorrance H. Hamilton Building, Center City Campus of  
Thomas Jefferson University
•  9th Annual Brain Tumor Symposium 
October 25, 2019 
Philadelphia, PA
•  2nd Annual New Jersey  
Neurovascular Symposium 
November 2019
•  31st Annual Pan Philadelphia  
Neurosurgery Conference 
December 6, 2019 
The Union League of Philadelphia
For additional information regarding these and other Jefferson CPD  
programs, please visit our website at CME.Jefferson.edu or call the Office  
of CPD at 877-JEFF-CPD (877-533-3273).  
Sidney Kimmel Medical College at Thomas Jefferson University is  
accredited by the ACCME to provide continuing medical education  
for physicians.
Many of the activities above offer additional CE accreditations.
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PHIL ADELPHIA  •   MONTGOMERY COUNT Y  •   BUCKS COUNT Y  •   SOUTH JERSEY
Jefferson Health
•  One of the largest brain tumor programs in the nation and currently 
researching a new immunotherapy for treating glioblastomas
•  Internationally recognized experts in endovascular neurosurgery, 
performing more than 400 aneurysms and brain AVM  
procedures a year
•  One of the first and only clinical, academic and research centers 
dedicated to headache disorders 
•  Specialists treating more spine disorders and injuries than any 
other hospital in the region
•  One of the highest volume medical and surgery epilepsy centers 
in the nation, with some of the country’s most experienced 
specialists in neurostimulation implantation
The Vickie and Jack Farber Institute for Neuroscience – 
Jefferson Health – where the brightest minds are preventing, 
treating and finding cures for brain and spine disorders.
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